Featured Clinical Trial
DUET: Sparsentan in FSGS
The DUET trial is an interventional study that will determine how effective the drug Sparsentan is at reducing the urine protein / creatinine ratio over 8 weeks.
Who is Eligible?
Males and females between the ages of 8 and 75 years old with biopsy proven FSGS, or a proven genetic mutation transplant. Click HERE to see the other criteria that determine who is eligible to participate.
How Can I Participate?
There are currently over 30 study sites across the United States that are actively recruiting patients! To see that list, click HERE.
Don’t see a location near you? No worries! The DUET trial will reimburse you for any travel costs to a study site.
All study-related health exams and medications will be provided at no cost.
Click HERE to learn more about participating in the DUET Study.